Anti GPRC5D x CD3 monoclonal bispecific antibody - Integral Molecular
Alternative Names: Anti-CD3 x anti-GPCR5D bispecific monoclonal antibody - Integral Molecular; GPRC5DxCD3 bsAb - Integral MolecularLatest Information Update: 15 Jun 2024
At a glance
- Originator Integral Molecular
- Class Antineoplastics; Bispecific antibodies; Immunoproteins; Monoclonal antibodies
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 11 Jun 2023 Anti GPRC5D x CD3 monoclonal bispecific antibody - Integral Molecular is available for licensing as of 11 Jun 2023. https://www.integralmolecular.com/partnering/ (Integral Molecular pipeline, June 2023)
- 14 Apr 2023 Preclinical trials in Multiple myeloma in USA (Parenteral) (Integral Molecular pipeline, June 2023)